IL163745A0 - Use of adenoviruses mutated in the va genes for cancer treatment - Google Patents

Use of adenoviruses mutated in the va genes for cancer treatment

Info

Publication number
IL163745A0
IL163745A0 IL16374503A IL16374503A IL163745A0 IL 163745 A0 IL163745 A0 IL 163745A0 IL 16374503 A IL16374503 A IL 16374503A IL 16374503 A IL16374503 A IL 16374503A IL 163745 A0 IL163745 A0 IL 163745A0
Authority
IL
Israel
Prior art keywords
cancer treatment
genes
adenovirus
adenoviruses
mutated
Prior art date
Application number
IL16374503A
Other languages
English (en)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of IL163745A0 publication Critical patent/IL163745A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10364—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL16374503A 2002-03-26 2003-03-25 Use of adenoviruses mutated in the va genes for cancer treatment IL163745A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200716 2002-03-26
PCT/ES2003/000140 WO2003080083A1 (fr) 2002-03-26 2003-03-25 Utilisation d'adenovirus mutes dans les genes va en vue du traitement du cancer

Publications (1)

Publication Number Publication Date
IL163745A0 true IL163745A0 (en) 2005-12-18

Family

ID=27772025

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16374503A IL163745A0 (en) 2002-03-26 2003-03-25 Use of adenoviruses mutated in the va genes for cancer treatment
IL163745A IL163745A (en) 2002-03-26 2004-08-26 Use of adenoviruses mutated in the va and vaii genes for the preparation of pharmaceutical compositions for cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL163745A IL163745A (en) 2002-03-26 2004-08-26 Use of adenoviruses mutated in the va and vaii genes for the preparation of pharmaceutical compositions for cancer treatment

Country Status (14)

Country Link
US (3) US7344711B2 (fr)
EP (2) EP1498129B1 (fr)
JP (2) JP2005526099A (fr)
AT (1) ATE309812T1 (fr)
AU (1) AU2003226835B2 (fr)
BR (1) BR0308634A (fr)
CA (1) CA2478616C (fr)
DE (1) DE60302350T2 (fr)
DK (1) DK1498129T3 (fr)
ES (1) ES2248764T3 (fr)
HK (1) HK1071060A1 (fr)
IL (2) IL163745A0 (fr)
MX (1) MXPA04009204A (fr)
WO (1) WO2003080083A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526099A (ja) * 2002-03-26 2005-09-02 オンコリティクス バイオテック， インコーポレイティッド 癌治療のための、ｖａ遺伝子が変異したアデノウイルスの使用
CA2617600A1 (fr) 2005-08-01 2007-09-07 University Technologies International, Inc. Reovirus attenue
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007103825A2 (fr) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Polythérapie avec un adénovirus oncolytique
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
ES2355882B1 (es) 2009-03-24 2012-02-13 INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer.
WO2012121071A1 (fr) * 2011-03-04 2012-09-13 国立大学法人大阪大学 Vecteur adénoviral dans lequel les va-arn ne sont pas exprimés
EP2971008B1 (fr) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Compositions d'adénovirus oncolytiques
EP3390428B1 (fr) 2016-02-23 2019-09-25 Salk Institute for Biological Studies Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2020047345A1 (fr) 2018-08-31 2020-03-05 Yale University Compositions et méthodes d'utilisation d'anticorps de pénétration cellulaire en association avec des modulateurs de points de contrôle immunitaire
WO2021024207A1 (fr) 2019-08-05 2021-02-11 Mesoblast International Sarl Compositions cellulaires comprenant des vecteurs viraux et procédés de traitement
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
WO2024081736A2 (fr) 2022-10-11 2024-04-18 Yale University Compositions et procédés d'utilisation d'anticorps de pénétration cellulaire

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648301B2 (ja) * 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 真核細胞の形質転換のための補助ｄｎａを含むベクター
US5079159A (en) * 1983-12-27 1992-01-07 Genetics Institute, Inc. Method for making tissue plasminogen activator
US5002874A (en) * 1987-09-17 1991-03-26 Genetics Institute, Inc. Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
WO1999057296A1 (fr) * 1998-05-01 1999-11-11 Genzyme Corporation Vecteurs adenoviraux a deletion partielle
CA2388807C (fr) * 1999-11-12 2013-08-06 Matthew C. Coffey Virus pour le traitement des troubles de la proliferation cellulaire
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
JP2005503797A (ja) * 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
JP2005526099A (ja) * 2002-03-26 2005-09-02 オンコリティクス バイオテック， インコーポレイティッド 癌治療のための、ｖａ遺伝子が変異したアデノウイルスの使用
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders

Also Published As

Publication number Publication date
BR0308634A (pt) 2005-02-15
AU2003226835A1 (en) 2003-10-08
ATE309812T1 (de) 2005-12-15
HK1071060A1 (en) 2005-07-08
US20110053249A1 (en) 2011-03-03
ES2248764T3 (es) 2006-03-16
EP1498129B1 (fr) 2005-11-16
EP1605053A1 (fr) 2005-12-14
US7344711B2 (en) 2008-03-18
JP2005526099A (ja) 2005-09-02
DE60302350T2 (de) 2006-08-03
US20060233753A1 (en) 2006-10-19
JP2010184940A (ja) 2010-08-26
AU2003226835B2 (en) 2006-11-09
US20090202489A2 (en) 2009-08-13
CA2478616C (fr) 2012-05-29
US20080089864A1 (en) 2008-04-17
DK1498129T3 (da) 2006-04-03
CA2478616A1 (fr) 2003-10-02
IL163745A (en) 2010-02-17
DE60302350D1 (de) 2005-12-22
MXPA04009204A (es) 2004-11-26
WO2003080083A1 (fr) 2003-10-02
EP1498129A1 (fr) 2005-01-19

Similar Documents

Publication Publication Date Title
HK1071060A1 (en) Use of adenoviruses mutated in the va genes for cancer treatment
WO2004066941A3 (fr) Profils d'expression destines au cancer du colon et procedes d'utilisation
WO2004035803A3 (fr) Procede et acides nucleiques permettant d'ameliorer le traitement de troubles de la proliferation de celllules mammaires
EP2639319A3 (fr) Polymorphismes génétiques associés au psoriasis, procédés de détection et utilisations associées
AU2002360820A8 (en) Compositions for dna mediated gene silencing
WO2008005562A3 (fr) Compositions de silençage de l'arn, et méthodes de traitement de la chorée de huntington
WO2006037462A3 (fr) Marqueurs du cancer
WO2001077164A8 (fr) Diagnostic de maladies associees a l'apoptose
WO2006074351A3 (fr) Terminateurs nucleotidiques reversibles et leurs utilisations
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
WO2007085497A8 (fr) Marqueurs de prévision des résultats d'un traitement à l'anthracycline
WO2005032495A3 (fr) Profils d'expression genique et leurs methodes d'utilisation
WO2005010149A3 (fr) Vecteurs adenoviraux du sous-groupe b pour le traitement de maladies
AU2002359645A8 (en) Targeted genetic risk-stratification using microarrays
MXPA05008329A (es) Uso de un polimorfismo novedoso en el gen hsgk1 para el diagnostico de hipertonia y el uso de la familia del gen sgk en el diagnostico y terapia del sindrome q/t largo.
WO2003000896A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-5
MXPA05005120A (es) Secuencias de adn de la region genomica tcd de photorhabdus luminescens.
WO2002101048A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-7
AU2002212232A1 (en) Nucleotide sequences which code for the dps gene
AU2001287682A1 (en) Nucleotide sequences coding for the ftsx gene
AU2001282084A1 (en) Nucleotide sequences which code for the sigh gene
Pan et al. Sequencing, tissue distribution and physical mapping of the porcine homologue of cardiomyopathy associated 3 (CMYA3).
WO2002089829A3 (fr) Sequences
AU7666900A (en) Nucleotide sequences derived from genes coding for trimethylamine n-oxide reductase, uses thereof in particular for detecting bacteria
AU2001291729A1 (en) Nucleotide sequences which code for the cobw gene

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)